Arcellx and Kite have partnered on the development of anitocabtagene autoleucel (anito-cel), a BCMA CAR T cell therapy for multiple myeloma. The companies have designed a global Phase 3 trial, iMMagine-3, to evaluate the efficacy and safety of anito-cel in patients who have received prior treatment with an immunomodulatory drug and an anti-CD38 monoclonal antibody.

The trial will compare anito-cel to the standard of care in patients with relapsed and/or refractory multiple myeloma who have received one to three prior lines of therapy. Kite’s manufacturing facility in Frederick, Maryland will produce anito-cel for the trial, following the completion of a technical transfer from a third-party contract manufacturing organization.

Arcellx’s Chairman and Chief Executive Officer, Rami Elghandour, stated that the iMMagine-3 trial will target a large patient population with a significant unmet need. The completion of the technical transfer to Kite has accelerated the development program and enabled broader patient access to anito-cel.

Cindy Perettie, Executive Vice President of Kite, emphasized the importance of manufacturing quality and speed for patients with relapsed and/or refractory multiple myeloma. Kite’s manufacturing expertise will support anito-cel’s position as a potential best-in-class cell therapy.

iMMagine-3 is expected to begin in the second half of 2023. Preliminary data from the iMMagine-1 trial is anticipated by the end of the year. Arcellx and Kite remain committed to advancing anito-cel as a promising treatment option for patients with multiple myeloma.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.